Company: ADPT
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030913
Chunk: 187

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 187
---
 31, 2023

        130,660

        Interest expense

        11,580

        Revenue interest paid

        (6,589
        )

        Revenue interest payable

        (2,372
        )

        Revenue interest liability, net at December 31, 2024

        133,279

        Less: Current portion at December 31, 2024

        (865
        )

        Revenue interest liability, net, less current portion at December 31, 2024
         
        $
        132,414

      Interest expense was $4.2 million for the year ended December 31, 2022. Revenue interest payable of $2.4 million and $2.3 million was included within the accounts payable balance on the consolidated balance sheet as of December 31, 2024 and 2023, respectively.

12.Commitments and ContingenciesLegal Proceedings We are subject to claims and assessments from time to time in the ordinary course of business. We will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. We were not party to any material legal proceedings as of December 31, 2024.Indemnification Agreements In the ordinary course of business, we may provide indemnification of varying scope and terms to vendors, lessors, customers and other parties with respect to certain matters including, but not limited to, losses arising out of breach of our agreements with them or from intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with members of our board of directors and certain of our executive officers that will require us to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments that we could be required to make under these indemnification agreements is, in many cases, unlimited. We have not incurred any material costs as a result of such indemnifications and are not currently aware of any indemnification claims.

13.Shareholders’ EquityCommon StockOur common stock has no preferences or privileges and is not redeemable. Holders of our common stock are entitled to one vote for each share of common stock held.